These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9885815)

  • 1. Transglutaminase as the agent of neurodegenerative diseases due to polyglutamine expansion.
    Kahlem P; Green H; Djian P
    Pathol Biol (Paris); 1998 Nov; 46(9):681-2. PubMed ID: 9885815
    [No Abstract]   [Full Text] [Related]  

  • 2. The multifaceted role of transglutaminase in neurodegeneration: review article.
    Karpuj M; Steinman L
    Amino Acids; 2004 Jul; 26(4):373-9. PubMed ID: 15290343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Aggregation and toxicity of the proteins with polyQ repeats].
    Leźnicki P
    Postepy Biochem; 2005; 51(2):215-22. PubMed ID: 16209359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transglutaminase and diseases of the central nervous system.
    Hoffner G; Djian P
    Front Biosci; 2005 Sep; 10():3078-92. PubMed ID: 15970562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible involvement of transglutaminase-catalyzed reactions in the physiopathology of neurodegenerative diseases.
    Martin A; Giuliano A; Collaro D; De Vivo G; Sedia C; Serretiello E; Gentile V
    Amino Acids; 2013 Jan; 44(1):111-8. PubMed ID: 21938398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Transglutaminase and neurodegenerative diseases].
    Liu Z; Zeng J; Zeng S; Tang B; Wang J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2015 Aug; 32(4):562-6. PubMed ID: 26252108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transglutaminase is linked to neurodegenerative diseases.
    Muma NA
    J Neuropathol Exp Neurol; 2007 Apr; 66(4):258-63. PubMed ID: 17413316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pathogenic agent in Drosophila models of 'polyglutamine' diseases.
    McLeod CJ; O'Keefe LV; Richards RI
    Hum Mol Genet; 2005 Apr; 14(8):1041-8. PubMed ID: 15757976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transglutaminase-catalyzed post-translational modifications of proteins in the nervous system and their possible involvement in neurodegenerative diseases.
    De Vivo G; Gentile V
    CNS Neurol Disord Drug Targets; 2008 Oct; 7(4):370-5. PubMed ID: 18991665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validity of mouse models for the study of tissue transglutaminase in neurodegenerative diseases.
    Bailey CD; Graham RM; Nanda N; Davies PJ; Johnson GV
    Mol Cell Neurosci; 2004 Mar; 25(3):493-503. PubMed ID: 15033177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis of inclusion bodies in (CAG)n/Qn-expansion diseases with special reference to the role of tissue transglutaminase and to selective vulnerability.
    Cooper AJ; Sheu KF; Burke JR; Strittmatter WJ; Gentile V; Peluso G; Blass JP
    J Neurochem; 1999 Mar; 72(3):889-99. PubMed ID: 10037459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue transglutaminase: a novel pharmacological target in preventing toxic protein aggregation in neurodegenerative diseases.
    Wilhelmus MM; van Dam AM; Drukarch B
    Eur J Pharmacol; 2008 May; 585(2-3):464-72. PubMed ID: 18417122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the transglutaminase enzymes in the nervous system and their possible involvement in neurodegenerative diseases.
    De Vivo G; Di Lorenzo R; Ricotta M; Gentile V
    Curr Med Chem; 2009; 16(36):4767-73. PubMed ID: 19929789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical mechanisms for a possible involvement of the transglutaminase activity in the pathogenesis of the polyglutamine diseases: minireview article.
    Pepe I; Occhino E; Cella G; Luongo A; Guardascione F; Gentile V
    Amino Acids; 2004 Jul; 26(4):431-4. PubMed ID: 15290350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible physiopathological effects of the transglutaminase activity on the molecular mechanisms responsible for human neurodegenerative diseases.
    Iannaccone M; Titta F; Serretiello E; Monfregola M; Gentile V
    Recent Pat CNS Drug Discov; 2014; 9(2):76-84. PubMed ID: 25386917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue transglutaminase-catalyzed formation of high-molecular-weight aggregates in vitro is favored with long polyglutamine domains: a possible mechanism contributing to CAG-triplet diseases.
    Gentile V; Sepe C; Calvani M; Melone MA; Cotrufo R; Cooper AJ; Blass JP; Peluso G
    Arch Biochem Biophys; 1998 Apr; 352(2):314-21. PubMed ID: 9587422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transglutaminase-catalyzed crosslinking in neurological disease: from experimental evidence to therapeutic inhibition.
    Hoffner G; André W; Vanhoutteghem A; Souès S; Djian P
    CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):217-31. PubMed ID: 19811443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transglutaminase inhibition as a possible therapeutical approach to protect cells from death in neurodegenerative diseases.
    Iannaccone M; Serretiello E; De Vivo G; Martin A; Stefanile A; Titta F; Gentile V
    Recent Pat CNS Drug Discov; 2013 Aug; 8(2):161-8. PubMed ID: 23688272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transglutaminase activity as a possible therapeutical target in neurodegenerative diseases.
    Iannaccone M; Titta F; Serretiello E; De Vivo G; Martin A; Gentile V
    Recent Pat CNS Drug Discov; 2013 Dec; 8(3):235-42. PubMed ID: 24286449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mechanisms of neurodegeneration in polyglutamine diseases].
    Tsuji S
    Rinsho Shinkeigaku; 2003 Nov; 43(11):901-2. PubMed ID: 15152498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.